MarketCap
Facebook
X
TelegramQuarterly report 2025-Q2
added 07-31-2025
Integra LifeSciences Holdings Corporation Interest Expense 2011-2026 | IART
Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.Includes:
- Interest on bank loans
- Interest on corporate bonds
- Interest on leases
- Interest on credit lines and overdrafts
High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.
Low interest expenses with high profits are a sign of financial stability.
Annual Interest Expense Integra LifeSciences Holdings Corporation
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3.94 M | 3.72 M | 12 M | 50.4 M | 71.6 M | 54 M | 64.7 M | 35 M | 25.8 M | 23.5 M | 22 M | 19.7 M | 22.2 M | 27.6 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 71.6 M | 3.72 M | 31.2 M |
Quarterly Interest Expense Integra LifeSciences Holdings Corporation
| 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -1.95 M | -144 K | 2.11 M | 1.44 M | -610 K | 471 K | -155 K | 12.1 M | - | 12.8 M | 12.2 M | 11.7 M | - | 12.2 M | 13.1 M | 12.9 M | - | 20.8 M | 15.7 M | 17.8 M | - | 14 M | 13.4 M | 13.1 M | - | 14.5 M | 17.5 M | 18.8 M | - | 6.76 M | 6.18 M | 5.13 M | - | 6.3 M | 6.59 M | 6.37 M | - | 6.46 M | 5.48 M | 5.47 M | - | 5.91 M | 5.38 M | 5.14 M | - | 5.32 M | 4.96 M | 4.8 M | - | 5.55 M | 7.1 M | 7.93 M | - | 7.59 M | 6.72 M | 5.47 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 20.8 M | -1.95 M | 8.19 M |
Interest Expense of other stocks in the Medical devices industry
| Issuer | Interest Expense | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Abiomed
ABMD
|
58.7 M | - | - | $ 17.2 B |  USA |
 |
Allied Healthcare Products
AHPI
|
191 K | - | 3.58 % | $ 2.21 M | USA |
 |
Alphatec Holdings
ATEC
|
24.9 M | $ 20.62 | -2.02 % | $ 2.95 B | USA |
 |
Acutus Medical
AFIB
|
5.66 M | - | -26.83 % | $ 2.62 M | USA |
 |
Cognyte Software Ltd.
CGNT
|
-1.61 M | $ 8.94 | -4.88 % | $ 642 M |  Israel |
 |
Apyx Medical Corporation
APYX
|
2.48 M | $ 3.51 | 0.29 % | $ 122 M | USA |
 |
Boston Scientific Corporation
BSX
|
305 M | $ 94.69 | -0.69 % | $ 139 B | USA |
 |
Bio-Rad Laboratories
BIO
|
48.9 M | $ 302.54 | -0.15 % | $ 8.54 B | USA |
 |
Apollo Endosurgery
APEN
|
4.67 M | - | - | $ 475 M | USA |
 |
Conformis
CFMS
|
2.02 M | - | - | $ 16.4 M | USA |
 |
Cardiovascular Systems
CSII
|
1.63 M | - | 0.15 % | $ 844 M | USA |
 |
Cutera
CUTR
|
-244 K | - | -10.19 % | $ 1.99 M | USA |
 |
BioSig Technologies
BSGM
|
23 K | - | 37.08 % | $ 85.7 M | USA |
 |
Bruker Corporation
BRKR
|
-38.2 M | $ 47.03 | -0.17 % | $ 7.01 K | USA |
 |
Electromed
ELMD
|
78 K | $ 28.76 | -1.25 % | $ 243 M | USA |
 |
Eargo
EAR
|
549 K | - | - | $ 10.2 M | USA |
 |
Abbott Laboratories
ABT
|
376 M | $ 124.33 | -0.77 % | $ 216 B | USA |
 |
EDAP TMS S.A.
EDAP
|
232 K | $ 3.29 | - | $ 123 M |  France |
 |
Second Sight Medical Products
EYES
|
1.19 M | - | -0.97 % | $ 54.4 M | USA |
 |
IRadimed Corporation
IRMD
|
164 K | $ 97.43 | 0.15 % | $ 1.23 B | USA |
 |
Neovasc
NVCN
|
133 K | - | - | $ 111 M |  Canada |
 |
LivaNova PLC
LIVN
|
1.01 M | $ 61.5 | -0.06 % | $ 3.34 B |  Britain |
|
LENSAR
LNSR
|
660 K | $ 11.7 | 0.6 % | $ 135 M | USA |
 |
Dynatronics Corporation
DYNT
|
410 K | - | 14.99 % | $ 929 K | USA |
 |
Align Technology
ALGN
|
7.68 M | $ 155.44 | -0.45 % | $ 11.6 B | USA |
 |
Accuray Incorporated
ARAY
|
13 M | $ 0.84 | 1.76 % | $ 86.3 M | USA |
 |
Avinger
AVGR
|
1.72 M | - | -20.74 % | $ 369 K | USA |
 |
ClearPoint Neuro
CLPT
|
-40 K | $ 13.64 | -0.41 % | $ 369 M | USA |
 |
FONAR Corporation
FONR
|
347 K | $ 18.55 | -0.05 % | $ 122 M | USA |
 |
Orthofix Medical
OFIX
|
-9.62 M | $ 14.94 | -1.45 % | $ 570 M |  Curacao |
 |
AxoGen
AXGN
|
-199 K | $ 31.45 | -3.91 % | $ 1.39 B | USA |
 |
Axonics Modulation Technologies
AXNX
|
-2.43 M | - | - | $ 3.31 B | USA |
 |
CONMED Corporation
CNMD
|
37.3 M | $ 40.79 | 0.47 % | $ 1.26 B | USA |
 |
Profound Medical Corp.
PROF
|
146 K | $ 7.57 | -3.88 % | $ 180 M | Canada |
 |
OrthoPediatrics Corp.
KIDS
|
-1.07 M | $ 17.51 | -1.44 % | $ 404 M | USA |
 |
Globus Medical
GMED
|
2.2 M | $ 86.48 | -0.95 % | $ 11.7 B | USA |